[The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)].
In 12 parkinsonian patients aged from 40--76 years the L-dopa-potentiating effect of MIF was investigated using a doubleblind crossover design. MIF was given i.v. in a dose of 200 mg. The following psychological tests were carried out 4 times after the injection of MIF at hourly intervals: Purdue pegboard, Minnesota-Rate of manipulation test, 2-key-tapping, simple and complex reaction time and a state of well-being scale. The results revealed a marked effect on finger dexterity, drive and complex reaction time. That means MIF does not only lead to an improvement of psychomotor performance but also of cognitive functions. In contrast thereto the influence on the state of well-being was less impressive.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004644:Emotions / Q000187:drug effects*; D005260:Female; D006801:Humans; D009075:MSH Release-Inhibiting Hormone / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects*; D010300:Parkinson Disease / Q000188:drug therapy / Q000523:psychology*; D011930:Reaction Time / Q000187:drug effects; D013997:Time Factors
D009075:MSH Release-Inhibiting Hormone
Der Einfluss von MIF (Melanozyteninhibierender Faktor) auf Psychomotorik und Stimmungsverhalten von Parkinsonkranken.